Basit S. Athar
Harvard University
10 Papers
11 Citations
Basit S. Athar is an academic researcher from Harvard University. The author has contributed to research in topics: Radiation therapy & Proton therapy. The author has an hindex of 6, co-authored 10 publications. Previous affiliations of Basit S. Athar include Rensselaer Polytechnic Institute & Hampton University.
Chat about Author
Papers
Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans
Basit S. Athar,Harald Paganetti +1 more
TL;DR: In terms of out-of-field risks, IMRT offers advantage close to the primary field and an increasing advantage for passive proton therapy is noticed with increasing distance to the field, and scanning proton beam therapy shows the lowest risks.
104
Comparison of out-of-field photon doses in 6 MV IMRT and neutron doses in proton therapy for adult and pediatric patients
TL;DR: There seem to be three geometrical areas when comparing the out-of-target dose from IMRT and (passive scattered) proton treatments, close to the target (in-field, not analyzed here) protons offer a distinct advantage due to the lower integral dose and at larger distances to the field (beyond approximately 25 cm), protons offers an advantage, resulting in doses that are roughly a factor of 2-3 lower.
A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models
TL;DR: The treatment-related second cancer risks in organs outside the primary beam due to 3D-CRT and IMRT is small and new risk assessment techniques need to be investigated to address the concern of radiation-induced second cancers from prostate treatments, particularly focusing on risks to organs inside thePrimary beam.
53
Neutron equivalent doses and associated lifetime cancer incidence risks for head & neck and spinal proton therapy
Basit S. Athar,Harald Paganetti +1 more
TL;DR: This work simulated the absorbed equivalent doses to various organs distant to the field edge assuming proton therapy treatments of brain or spine lesions and demonstrated that organ-specific neutron equivalent doses are age (stature) dependent.
46
Adjuvant radiation therapy for early stage seminoma: Proton versus photon planning comparison and modeling of second cancer risk
Jason A. Efstathiou,Jonathan J. Paly,Hsiao-Ming Lu,Basit S. Athar,Maryam Moteabbed,Andrzej Niemierko,Judith Adams,Justin E. Bekelman,William U. Shipley,Anthony L. Zietman,Harald Paganetti +10 more
TL;DR: The use of protons provided a favorable dose distribution with an ability to limit unnecessary exposure to critical normal structures in the treatment of early-stage seminoma and it is expected that this will translate into decreased acute toxicity and reduced risk of second cancers, for which prospective studies are warranted.
38